CRIS
Curis, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.35
−1.46%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.1x
Market Cap
$3.27M
MomentumView details →
1D Return
−1.46%
YTD Return
−93.31%
RSI (14)
21.2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.1x
Market Cap
$3.27M
RSI (14)
21.2
MomentumView details →
1D Return
−1.46%
YTD Return
−93.31%
SummaryUpdated Jun 1, 2026
Curis, Inc. (NASDAQ:CRIS) is a biotechnology company founded in 2000 and headquartered in Lexington, Massachusetts. The company specializes in discovering and developing drug candidates for treating various human cancers, with a focus on blood cancers and solid tumors. Since going public in 2000, Curis has evolved from a broader drug discovery platform to concentrate primarily on oncology therapeutics, particularly through its lead compound <b>emavusertib</b>, which targets specific genetic mutations in cancer patients.
Similar companies
Latest newsMore news →
Curis, Inc. priced a public offering of 3,733,334 shares of common stock (or pre-funded warrants) and warrants to purchase up to 3,733,334 shares of common stock at a combined price of $1.50 per share and accompanying warrant, raising approximately $5.6 million from healthcare-focused institutional investors.23d agoCuris dosed the first five patients in its TakeAim CLL study for emavusertib in patients with Chronic Lymphocytic Leukemia.37d agoCuris Inc. announced updated positive clinical trial results for its investigational drug emavusertib and expanded trial timeline guidance.44d ago